神戸大学 · 医学部附属病院 · 特定助教

研究キーワードfemoroacetabular impingement・hip arthroscopy・bone metastasis surgery・soft tissue sarcoma chemotherapy・osteosarcoma metastasis・developmental dysplasia of the hip・labral tear outcomes・palliative orthopedic oncology

研究分野整形外科学

ここは公開データのプレビューです。個別の適合理由、連絡角度、保存機能はログイン後に利用できます。

• Solitary pancreatic lesion as the initial metastasis from osteosarcoma: Report of a rare case.2020 · 2020年07月, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 25(4) (4), 724 - 728, 英語, 国内誌
• Arthroscopic Treatment of Femoroacetabular Impingement in Patients With and Without Borderline Developmental Dysplasia of the Hip: A Systematic Review and Meta-analysis.2019 · BACKGROUND: Based on previous studies, it is difficult to discern whether patients who have femoroacetabular impingement (FAI) with borderline developmental dysplasia of the hip (BDDH) would benefit from arthroscopy when compared with patients without BDDH. PURPOSE: To evaluate the existing comparative literature on arthroscopic findings, procedures, patient-reported outcomes (PROs), and failures in patients who have FAI with BDDH compared with those without BDDH. STUDY DESIGN: Systematic review; Level of evidence, 3. METHODS: The PubMed, Embase, and Ovid databases were searched for studies published up to August 31, 2019, that reported outcomes after arthroscopy to treat patients who had FAI with BDDH. Included studies were required to have patients diagnosed with FAI and BDDH who were treated arthroscopically and compared with control patients (FAI without BDDH). Arthroscopic findings, PROs, and revision or total hip arthroplasty (THA) conversion rates were compared between groups. RESULTS: Included in the review were 4 articles (933 patients). Patients who had FAI with BDDH were defined as having a lateral center-edge angle (LCEA) of either 18° to 25° or 20° to 25°; for control patients, the maximum LCEA was 40°. Across the studies, there were 224 patients who had FAI with BDDH compared with 709 control patients; the mean follow-up time ranged from 21.6 to 31.3 months among the groups. Improvements were shown across all PROs in each study. Random-effects meta-analysis indicated no statistically significant differences in postoperative PROs, the risk for revision surgery, or conversion to THA between the patients who had FAI with versus without BDDH. CONCLUSION: The results of the current review indicated that hip arthroscopy produced similar short-term outcomes between patients who had FAI with versus without BDDH.
• Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.2018 · BACKGROUND: The prognosis of patients with metastatic or advanced sarcomas is poor and there are few options for treatment. Several studies have shown that gemcitabine and docetaxel (GD) combination chemotherapy has antitumor activity against various subtypes of sarcoma. Recently, some studies have shown a favourable outcome for GD combination chemotherapy for relapsed high-grade osteosarcoma and spindle cell sarcoma of bone. If the effectiveness of GD is proven, this will result in new treatment options for advanced bone and soft tissue sarcomas (STS). The aim of this prospective Phase 2 study is to evaluate the efficacy and toxicity of the GD combination in patients with advanced bone sarcomas and STS. METHODS: This is a Phase 2, single-arm, open-label study to investigate the efficacy and safety of combination chemotherapy with GD for advanced bone sarcomas and STS and will enrol 20 patients. The patients will receive gemcitabine 900 mg/m2 on Days 1 and 8, and docetaxel 70 mg/m2 on Day 8 in 3-week cycles until disease progression or other evidence of treatment failure. The primary aim of this study is to analyse GD's effect on progression-free survival (PFS). The secondary objectives are to analyse treatment efficacy and safety in terms of response rate, tumour control rate, overall survival, and adverse event rate. The length of follow-up will be 5 years. DISCUSSION: This study will evaluate the efficacy and safety of combination therapy with gemcitabine and docetaxel for bone sarcomas and STS. If this combination proves to be acceptable, it could be used for as second, third, or later line therapy for patients with sarcomas (especially bone sarcomas). In the future, the role of various treatments, including GD therapy, will be clarified for specific subtypes of sarcoma. TRIAL REGISTRATION: This study was registered as UMIN000031004 (University Hospital Medical Information Network-Clinical Trial Registry: UMIN-CTR) on 1 March 1 2018 and with the Japan Registry of Clinical Trials (jRCT) as jRCTs051180042 on 30 January 2019. The posted information will be updated as needed to reflect protocol amendments and study progress.
• Cotyloid Fossa Coverage Percentages May Be Associated With Alpha Angle, Labral Tear, and Clinical Outcomes in Patients With Femoroacetabular Impingement.2015 · BACKGROUND: Within the hip joint, the anatomy of the acetabulum and cotyloid fossa is well established. There is little literature describing the association between the size of the cotyloid fossa relative to the acetabulum and characteristics of patients with femoroacetabular impingement (FAI). PURPOSE/HYPOTHESIS: The purpose was to calculate the cotyloid fossa coverage percentage in the acetabulum and determine its association with patient characteristics, radiographic parameters, intra-articular findings, and preoperative patient-reported outcomes in patients with FAI. We hypothesized there is an association between the cotyloid fossa coverage percentage of the acetabulum and characteristics of patients with FAI. STUDY DESIGN: Cross-sectional study; Level of evidence, 3. METHODS: Patients were included who underwent standard clinical 3-T magnetic resonance imaging of the hip and primary arthroscopic FAI correction surgery during 2015 and 2016. Exclusion criteria were age

• 小児骨肉腫における悪液質に伴う筋萎縮に対する抗酸化フラボノイドの効果 深瀬 直政, 澤田 良子, 原 仁美, 藤原 周一, 秋末 敏宏 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2024年04月01日 - 2027年03月31日2024 · KUID parsed section
• サルコペニアの骨格筋に対する経皮的炭酸ガス投与法の効果について 原 仁美, 竹森 俊幸, 河本 旭哉, 藤原 周一, 秋末 敏宏, 深瀬 直政, 澤田 良子 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2022年04月01日 - 2025年03月31日2022 · KUID parsed section
• 細胞移植を必要としない骨再生治療の創出-新規開発骨誘導型コラーゲンを用いた挑戦 深瀬 直政 日本学術振興会, 科学研究費助成事業, 若手研究, 神戸大学, 2021年03月01日 - 2023年03月31日2021 · KUID parsed section
• iPS細胞作製技術を用いた人工骨肉腫幹細胞の樹立と機能解明 河本 旭哉, 原 仁美, 深瀬 直政, 秋末 敏宏, 青井 貴之, 川上 洋平 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2018年04月01日 - 2021年03月31日 希少がんである骨肉腫細胞からiPS細胞作製技術を応用して幹細胞の性質を併せ持つ骨肉腫幹細胞を作製し，その性質について検討を行った． 骨肉腫細胞株MG-63にOCT3/4・KLF4・SOX2を遺伝子導入することで，骨肉腫とがん幹細胞の特性を持つ細胞の作製に成功した．同細胞は，幹細胞マーカーの発現上昇、細胞増殖能低下、薬剤耐性能・細胞遊走能・骨形成能の増強を認め，In vivoでの腫瘍形成能増強と腫瘍組織内の悪性度上昇を認めた。本研究によって，骨肉腫細胞に特定因子を導入することでがん幹細胞の特性を獲得し得ることが明らかとなり，骨肉腫の新たな病態理解や治療標的分子の同定，新規治療開発が期待される．2018 · KUID parsed section

• 公式プロフィール